All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Gilead Sciences Inc. on Thursday filed a new drug application with the FDA for a hepatitis B drug expected to capture a sizeable portion of the market. (BioWorld Today)
